Fax: (323) 865-0061
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme
Version of Record online: 4 FEB 2004
Copyright © 2004 American Cancer Society
Volume 100, Issue 6, pages 1213–1220, 15 March 2004
How to Cite
Chamberlain, M. C. and Tsao-Wei, D. D. (2004), Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer, 100: 1213–1220. doi: 10.1002/cncr.20072
- Issue online: 5 MAR 2004
- Version of Record online: 4 FEB 2004
- Manuscript Accepted: 17 DEC 2003
- Manuscript Revised: 9 DEC 2003
- Manuscript Received: 15 AUG 2003
- progression-free survival;
- recurrent glioblastoma multiforme;
The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS).
Forty patients (28 men and 12 women) ages 28–67 years (median age, 51.5 years), with recurrent glioblastoma multiforme were treated. All patients had been treated previously with surgery and involved-field radiotherapy (median dose, 60 grays [Gy]; range, 59–61 Gy). In addition, all patients were treated adjuvantly with either nitrosourea-based chemotherapy (21 patients: procarbazine, lomustine, and vincristine in 13 patients; carmustine in 8 patients) or temozolomide (19 patients). Twenty-one patients who were treated previously with a nitrosourea were treated with temozolomide at the time of first recurrence. Twenty-one patients were treated with CYC at the time of second recurrence, and 19 patients were treated with CYC at the time of first recurrence. CYC was administered intravenously on 2 consecutive days (750 mg/m2 per day) every 4 weeks (operationally defined as a single cycle). Neurologic and neuroradiographic evaluations were performed every 8 weeks.
All patients were evaluable. In total, 170 cycles of CYC (median, 2 cycles; range, 2–12 cycles) were administered. CYC-related toxicity included alopecia in all patients (100%), anemia in 6 patients (3.5%), thrombocytopenia in 7 patients (4.1%), and neutropenia in 9 patients (5.3%). Four patients required transfusions (two required red blood cell transfusion, and two required platelet transfusion). One patient developed neutropenic fever without bacteriologic confirmation. No treatment-related deaths occurred. Seven patients (17.5%; 95% confidence interval [95% CI], 8–33%) exhibited a neuroradiographic partial response, 11 patients (27.5%; 95% CI, 15–44%) had stable disease, and 22 patients (55%) had progressive disease after a single cycle of CYC. The time to tumor progression ranged from 2 months to 18 months (median, 2 months). Survival ranged from 3 months to 24 months (median, 4 months). In patients with either a neuroradiographic response or stable disease (n = 18 [45%]), the median time to tumor progression was 6 months (range, 4–18 months; 95% CI, 6–8 months), and the median survival was 10 months (range, 5–24 months; 95% CI, 8–10 months). The 6-month PFS rate was 20%.
CYC exhibited modest efficacy with acceptable toxicity in the current cohort of adult patients with recurrent glioblastoma multiforme, all of whom had previously experienced treatment failure after temozolomide chemotherapy. Cancer 2004. © 2004 American Cancer Society.